Universal Brain
Private Company
Funding information not available
Overview
Universal Brain is an early-stage neuroscience and AI company aiming to revolutionize the diagnosis and treatment of depression through objective, brain-based biomarkers. Its core platform, Neurotique™, combines a proprietary EEG headset with digital event-related potential (ERP) tasks and algorithms to subtype patients based on functional neural measures, moving beyond subjective symptom reporting. The company's initial focus is on reducing heterogeneity in clinical trials and aiding clinician decision-making, with the long-term goal of establishing a new data-driven standard in psychiatry.
Technology Platform
Integrated platform combining a proprietary EEG wearable, a digital ERP task interface (Neurotique™), and machine learning algorithms to subtype patients based on functional brain measures (neurotyping).
Opportunities
Risk Factors
Competitive Landscape
Competition includes other companies developing digital biomarkers for psychiatry (e.g., Alto Neuroscience using EEG & AI, Mindstrong, Karuna Health) and established clinical EEG service providers. Universal Brain differentiates with its specific focus on active ERP tasks and a defined 'neurotype' clustering approach.